Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Int J Cardiol. 2016 Jun 23;
Authors: Gori M, Volterrani M, Piepoli M, Senni M
Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.
PMID: 27378659 [PubMed - as supplied by publisher]